Craig D Logsdon, Ph.D.
University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd, Unit 0953, 2SCR2.2014
Houston, TX 77030
United States of America
(713) 563-3585 office
My laboratory is currently involved in several areas of research, for identifying novel therapeutic strategies and prognostic markers for pancreatic cancer (PCA).
- Investigation of the basis of PCA resistance to therapies. We recently compared gene expression profiles between PCA cell lines that are either sensitive or resistant to gemcitabine after gemcitabine treatments. We observed several genes that were elevated in all cells as well as genes elevated only in the resistant cells. Some of the elevated genes have functions that suggest they may be involved in the resistance. We will examine this hypothesis for each molecule using in vitro and in vivo studies in order to identify targets for therapeutic development.
- Developing technologies for treating PCA. We have previously identified several molecules that are autocrine regulators of the aggressive growth and metastasis observed in PCA. We are currently developing monoclonal antibodies to some of these targets. We are also conducting drug screens or optimizing lead compounds. Our goal is to develop useful therapies.
- Targeting PCA using nanoparticles or viruses. We are evaluating specific peptides with affinities for PCA cells as targeting moieties. We are also testing PCA specific gene promoters.
- Targeting the PCA tumor microenvironment. We are investigating interactions between PCA cells and cells of the tumor microenvironment including stellate, immune and vascular cells. We have observed important effects of these non-cancer cells on PCA tumors. We wish to exploit the microenvironment to treat PCA.